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Abstract p53 is a potent transcription factor which is regulated
by sequential multisite phosphorylation and acetylation. In this
paper, we identify threonine 18 of p53, a key site in regulating the
interaction between p53 and its regulatory partner MDM2, as a
novel site phosphorylated in vitro by purified recombinant casein
kinase 1 (CK1) N. Strikingly, phosphorylation of threonine 18 is
dependent upon prior phosphorylation of serine 15. These data
highlight an additional and physiologically important target
residue for CK1 in p53 and suggest a potential mechanism by
which sequential modification of a pivotal N-terminal residue in
p53 may occur following stress-activated modification of serine
15.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
The p53 tumour suppressor protein is a latent transcription
factor which is activated by a wide range of cellular stresses
(for review, see [1,2]). Activation of p53 in response to DNA
damage involves the release of p53 from complex formation
with its negative regulatory partner, MDM2, and is accompa-
nied by a sequential series of phosphorylation and acetylation
events which include phosphorylation of serines 15, 20 and 33
at the N-terminus of the protein (for review, see [3]). The
initial modi¢cation, phosphorylation of serine 15, is mediated
by the ATM protein kinase in vivo [4,5]. (Serine 15 and serine
37 can also be modi¢ed in vitro by the DNA-activated protein
kinase (DNA-PK) [6].) Serine 15 phosphorylation stimulates
p53-dependent transactivation through increased interaction
with p300/CBP [7,8] and may contribute to disruption of the
p53-MDM2 association [9,10]. Serine 15 modi¢cation may
also nucleate subsequent modi¢cations such as the acetylation
of the C-terminus through increased binding of p300/CBP
[11]. Recent evidence has also established that serine 20, a
key phosphorylation site which is modi¢ed following DNA
damage [12], plays a critical role in the disassociation of p53
and MDM2. Similarly, threonine 18 is phosphorylated in vivo
and can also contribute to the dissociation of the p53-MDM2
complex [13,14]. Moreover, extensive threonine 18 and serine
20 phosphorylation has been detected in a panel of human
breast cancers with wild-type (WT) p53 status [14] underscor-
ing their biomedical relevance. To date, however, the protein
kinases which phosphorylate threonine 18 and serine 20 have
not been established.
Protein kinase casein kinase 1 (CK1) comprises a family of
highly related, constitutively active serine/threonine protein
kinases (reviewed by [15]). CK1 is involved in controlling a
wide variety of di¡erent cellular events including protein turn-
over [16,17], nuclear import [18] and the cellular response to
DNA damage [19,20]. CK1 phosphorylates substrates which
are generally acidic on the N-terminal side of the target res-
idue and can utilise phosphorylated amino acids as recogni-
tion determinants [21,22]. Murine p53 is phosphorylated at
serines 4, 6 and 9 by protein kinase CK1 in vitro and in
cultured cells [23,24], but it has not yet been determined
whether CK1 can phosphorylate p53 from other species.
The involvement of CK1 in cellular events which in£uence
p53 function suggests that phosphorylation of p53 by CK1
may be an important regulatory route by which p53 can sense
changes in the environment.
In order to explore the phosphorylation of human p53 by
CK1, we have utilised a series of well-characterised GST-p53
fusion proteins as substrates. The spacing between serine 15
and threonine 18 suggested that phosphorylation of serine 15
might generate a recognition determinant through which
threonine 18 could become a CK1 substrate [21,22], the phos-
phorylation of which would be regulated through the serine
15 modi¢cation. In the present paper, we show that, in vitro,
this is indeed the case. The data therefore provide a potential
mechanism by which DNA damage-induced phosphorylation
of serine 15 may nucleate additional and physiologically im-
portant modi¢cation of the p53 protein.
2. Materials and methods
2.1. Expression and puri¢cation of glutathione-S-transferase p53
proteins
The ¢rst 42 amino acids (WT or a series of serine or threonine to
alanine mutants) of human p53 or the full length protein (WT or
serine 15 and/or 37 to alanine) were cloned into a pGEX-6P1 vector
(Amersham). The residues mutated in the GST-p53(1^42) proteins
were serines 15, 20, 33, 37 and threonine 18. Two serine to alanine
double changes at positions 6 and 9, and 15 and 37 were also in-
cluded. Serines 6 and 9 are sites for phosphorylation by CK1 in
murine p53 [23] whereas serines 15 and 37 are sites for phosphoryla-
tion in human p53 by DNA-PK [6]. The GST-murine p53 fusion
proteins ‘267’ (comprising amino acids 1^64) and ‘380’ (in which
serines 4, 6 and 9 are substituted by alanine residues) have been
used extensively and are described in detail elsewhere [24]. The clon-
ing, expression and puri¢cation of these proteins have been described
in detail elsewhere [7].
2.2. Phosphorylation of p53 in vitro
Phosphorylation of p53 by recombinant DNA-PK was carried out
according to the manufacturer’s instructions (Promega) using 1^2 Wg
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of the GST-p53 fusion protein as substrate. Control samples were
treated following the same protocol but in the absence of the protein
kinase (mock-treated). When labelling of the p53 was required,
[Q-32P]ATP was included in the reaction mix at a speci¢c activity of
250 Ci/mmol. Phosphorylation of p53 by recombinant CK1 (delta
isoform) was carried out according to the manufacturer’s instructions
(NEB) using 1^2 Wg of GST-p53 fusion protein as substrate and 5 U
of CK1. Double phosphorylation by DNA-PK and CK1 was carried
out as follows. Following phosphorylation by DNA-PK using unla-
belled ATP, the GST-p53 proteins were adsorbed onto glutathione-
Sepharose 4B beads (Pharmacia Biotech) and the beads were washed
twice in 25 mM Tris, pH 7.5, 50 mM NaCl, 5% (v/v) glycerol and
once in 50 mM Tris, pH 7.5, 10 mM MgCl2, 5 mM DTT. Phosphor-
ylation of the adsorbed proteins by CK1 was carried out for 30 min
according to the manufacturer’s instructions, using [Q-32P]ATP as
phosphate donor.
Phosphorylated proteins were resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and detected by
autoradiography. Prior to drying, the gels were stained to con¢rm
that the same amount of each GST-p53 protein is precipitated with
glutathione-Sepharose 4B beads and that the protein was phosphory-
lated stoichiometrically (this was evident from the decrease in electro-
phoretic mobility of the phosphorylated forms of the protein (data
not shown and see [7])). Quantitation was carried out using NIH
Image software following scanning of appropriately exposed autora-
diographs.
2.3. Phosphoamino acid analysis
Phosphoamino acid analysis was carried out as described by Kamps
and Sefton [25].
2.4. Human MDM2 protein (HDM2) binding in vitro
The binding of the HDM2 to p53 in vitro was carried out as
described recently [7] using GST pull-down assays in which the p53
was fused to GST (see above). The HDM2 was transcribed and trans-
lated in vitro using [35S]methionine.
3. Results
A series of GST-human p53 fusion proteins (comprising the
¢rst 42 amino acids of p53), in which known or potential
phosphorylation sites were substituted with alanine residues,
was used to investigate the phosphorylation of the N-terminus
by DNA-PK and CK1. Fig. 1A shows that most of these
proteins were substrates for DNA-PK. We have shown pre-
viously that the upper band in this experiment contains 2 mol
phosphate per mol of protein while the lower band represents
1 mol phosphate per mol of protein [7]. Mutation of serine 15
or 37 led to loss of the upper band, con¢rming that these
residues are DNA-PK target residues in vitro. When both
serines 15 and 37 were mutated, the fusion protein was only
a very poor DNA-PK substrate. GST was not phosphorylated
at all by DNA-PK. These data con¢rm that DNA-PK phos-
phorylates serines 15 and 37 in human p53 [6,7]. The human
p53 proteins were also phosphorylated in vitro by CK1 (Fig.
Fig. 1. Phosphorylation of GST-p53 fusion proteins by recombinant
DNA-PK and CK1N. GST-p53 proteins comprising the ¢rst 42 ami-
no acids or human p53 (WT and a series of mutants in which
known or potential phosphorylated residues were substituted by ala-
nine) were phosphorylated in vitro using recombinant DNA-PK (A)
or CK1N (B) and [Q-32P]ATP as phosphate donor. GST alone was
included as a negative control. As additional controls for the CK1
phosphorylation assays, phosphorylation of two GST-murine p53
proteins was carried out. These proteins were ‘267’ (comprising the
¢rst 64 amino acids or murine p53) and ‘380’ (in which the CK1
phosphorylation sites serines 4, 6 and 9 had been substituted by ala-
nine residues). The assay conditions were as described in Section 2.
The positions at which the phosphorylated proteins migrate in SDS-
PAGE are indicated.
Fig. 2. Phosphorylation of GST-p53 fusion proteins by CK1N, alone
or following stoichiometric phosphorylation by DNA-PK. GST-p53
fusion proteins were mock-phosphorylated or phosphorylated using
recombinant DNA-PK and unlabelled ATP as phosphate donor.
Following removal of the kinase and excess ATP, the proteins were
phosphorylated using recombinant CK1N and [Q-32P]ATP as phos-
phate donor. The panels are as follows. (A) The GST-murine p53
proteins 267 and 380. (B) GST alone, GST-WT human p53 and the
series of phosphorylation site mutants. The fold increase in phos-
phorylation by CK1 after prior phosphorylation by DNA-PK over
the phosphorylation by CK1 alone is indicated under the appropri-
ate lanes. (C) Phosphoamino acid analysis of the GST-WT human
p53 protein which was phosphorylated using recombinant DNA-PK
and unlabelled ATP, followed by CK1 phosphorylation in the pres-
ence of [Q-32P]ATP. The positions of unlabelled internal standards
(phosphoserine [S], phosphothreonine [T] and phosphotyrosine [Y])
are indicated by the dotted circles.
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1B). Substitution of serine 37 reduced the level of phosphor-
ylation while the S20A mutant could not be phosphorylated
by CK1, suggesting that these residues are either in vitro CK1
targets or are required for interaction with the protein kinase.
Strikingly, serines 6 and 9 of human p53, residues which are
key targets of CK1 in murine p53, are not phosphorylated by
CK1. GST-murine p53 proteins were also examined as con-
trols. As expected, the 267 protein (comprising amino acids 1^
64 of murine p53) was phosphorylated by CK1 whereas the
380 protein (in which serines 4, 6 and 9 are substituted by
alanine) was not a CK1 substrate. In general, the human p53
proteins were much weaker substrates than the murine p53
protein.
To determine whether serine 15 phosphorylation could in-
£uence the ability of CK1 to phosphorylate p53, the GST-p53
fusion proteins (both murine and human) were phosphory-
lated stoichiometrically using recombinant DNA-PK and ex-
cess unlabelled ATP as phosphate donor. The proteins were
bound to glutathione-Sepharose beads and washed prior to
the addition of CK1 and [Q-32P]ATP. Under the conditions
used, the rate of murine p53 phosphorylation by CK1 was
stimulated by up to 10-fold following prior phosphorylation
of serine 15 (Fig. 2A). CK1-mediated phosphorylation of the
380 protein was also observed, only after prior phosphoryla-
tion of serine 15, indicating that the residue(s) phosphorylated
by CK1 was neither serine 4, 6 or 9. WT human p53 and the
panel of phosphorylation site mutants were similarly exam-
ined (Fig. 2B). p53 which had previously been phosphorylated
at serine 15 (hereafter designated p53-15P) was phosphory-
lated by CK1 at least 50-fold more e¡ectively as compared
with the unphosphorylated protein. The GST moiety was not
phosphorylated by CK1 under these conditions. The role of
serine 15 in this process was underscored by the observation
that CK1-dependent phosphorylation of the 15A and 15A/
37A mutants, but not the 37A alone mutant, was barely de-
tectable and was only slightly higher as compared with the
mock DNA-PK-phosphorylated protein. After phosphoryla-
tion by DNA-PK, there were some di¡erences in the levels of
phosphorylation of the WT and several of the mutant pro-
teins. However, these di¡erences could also be discerned at the
basal level (i.e. when not phosphorylated by DNA-PK) and
may re£ect conformational di¡erences or a partial require-
ment of speci¢c serine residues to permit recognition or bind-
ing to the kinase. A convenient approach for determining the
e¡ect of serine 15 phosphorylation on subsequent phosphor-
ylation by CK1 was to measure the ratio of CK1-mediated
phosphorylation of p53-15P compared to the mock-phos-
phorylated proteins. These ratios are expressed as ‘fold in-
crease’ under the autoradiograph in Fig. 2B. These data re-
vealed that the 6A/9A, 37A and 20A mutants showed
increases comparable to WT p53 in their ability to be phos-
phorylated by CK1 following prior phosphorylation of serine
15. Strikingly, however, the ability of DNA-PK phosphoryla-
tion to stimulate CK1-mediated phosphorylation of the 18A
mutant was reduced by approximately 7-fold. This is consis-
tent with phosphorylation of threonine 18 in p53-15P by CK1.
To determine whether threonine 18 was indeed phosphory-
lated under these conditions, phosphoamino acid analysis of
the GST-WT human p53 protein was carried out. The data
(Fig. 2C) indicated that most of the radioactivity in the pro-
tein was present as phosphothreonine. There is only one
threonine residue in the N-terminal 42 amino acids of p53
and this is located at position 18 (Fig. 4).
These data indicate that, in the context of the N-terminal 42
amino acids of p53, threonine 18 is a substrate for phosphor-
ylation by CK1 as mediated by prior phosphorylation of ser-
ine 15. To determine whether this is a property of full length
Fig. 3. DNA-PK/CK1N-mediated phosphorylation of full length
GST-p53 fusion proteins and interaction with HDM2 in vitro. (A)
The GST-p53 fusion proteins comprising full length human p53
(WT, S15A or the S15,37A double mutant) were mock-phosphory-
lated (lanes 5^8) or phosphorylated using recombinant DNA-PK
and unlabelled ATP as phosphate donor (lanes 1^4). Following re-
moval of the kinase and excess ATP, the proteins were phosphory-
lated using recombinant CK1N and [Q-32P]ATP as phosphate donor.
GST alone was included as a negative control. (B) Binding of in vi-
tro-translated, radiolabelled HDM2 to phosphorylated and unphos-
phorylated GST-full length human p53.
Fig. 4. Schematic representation of the N-terminal 42 amino acids
of murine and human-p53. The amino acid sequences (in single let-
ter code) of human p53 (hu, top) and murine p53 (ms, bottom) are
shown in alignment. The highly conserved ‘Box I’ sequence [26] is
indicated, as are the positions of known physiological phosphoryla-
tion sites (with the letter P inside an ellipse and the position of the
phosphorylated residue indicated over the ellipse). The threonine 18
phosphorylation site is shown with a grey background. The CK1
phosphorylation sites in murine p53 at serines 4, 6 and 9 are also
indicated. An asterisk denotes the negatively charged residue at po-
sition 17.
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p53, GST-p53 fusion proteins comprising the full length p53
protein, either WT, 15A or 15A/37A, were mock-phosphory-
lated or phosphorylated with DNA-PK using unlabelled ATP
as phosphate donor. The data (Fig. 3) show that, in the ab-
sence of prior phosphorylation by DNA-PK, all three proteins
were phosphorylated by CK1 to an equal extent (lanes 5^8).
In contrast, the phosphorylation of WT p53 was stimulated
by up to 50-fold when the protein had previously been phos-
phorylated by DNA-PK (lane 2). When the 15A or 15A/37A
mutants were incubated with DNA-PK and unlabelled ATP
prior to CK1 phosphorylation (lanes 3 and 4), the stimulation
was considerably less e¡ective than with the WT protein,
although the levels of phosphorylation were slightly higher
than those in the absence of any prior phosphorylation. As
before, no phosphate was incorporated into the GST moiety.
These data indicate that phosphorylation of full length p53 is
stimulated by prior phosphorylation of the protein by DNA-
PK. Fig. 3B shows that when the p53 had been phosphory-
lated by DNA-PK and subsequently by CK1, the binding to
HDM2 in vitro was reduced by about 3-fold as compared
with the unphosphorylated protein. Phosphorylation by
DNA-PK alone or CK1 alone did not a¡ect HDM2 binding.
These data con¢rm the potential of threonine 18 modi¢cation
for regulating the interaction of p53 with HDM2 [13,14].
4. Discussion
In this paper, we have explored the phosphorylation of
human and murine p53 by the protein kinase CK1 in vitro.
The most striking observation which is evident from our data
is that prior phosphorylation of serine 15 in vitro can create a
potent recognition determinant for subsequent phosphoryla-
tion by CK1 (this applies to both human and murine p53).
Mutagenesis data and phosphoamino acid analysis indicate
that the residue phosphorylated by CK1 is threonine 18
(Fig. 2). Previous studies have established the importance of
phosphorylated residues in acting as recognition determinants
for phosphorylation by CK1 [21,22] and our data therefore
provide a potential mechanism by which serine 15 phosphor-
ylation may nucleate threonine 18 phosphorylation in the cell.
This would be consistent with an established role of serine 15
phosphorylation orchestrating sequential modi¢cation of oth-
er residues in p53 [11]. Such a role would be dependent on
DNA damage-induced modi¢cation of serine 15 (which is
mediated in vivo by ATM [4,5]) and would also be consistent
with the indication from yeast studies that CK1 activity is
pivotal to the DNA damage response [19,20]. Threonine 18
lies within a highly conserved element of the p53 protein (Fig.
4) which mediates p53 activation, regulation of the association
with MDM2 and control of the interaction with transcrip-
tional activators [4,5,7,8,10^12]. Moreover, recent evidence
indicates that threonine 18 phosphorylation contributes sig-
ni¢cantly to abrogating the p53-MDM2 interaction and is
therefore likely to be a signi¢cant factor in the p53 activation
process [13,14]. Our data con¢rm that threonine 18 phosphor-
ylation can partially block interaction of p53 with HDM2
(Fig. 3B). Threonine 18 modi¢cation may also be an impor-
tant factor in the p53 response to tumour development [14].
The identi¢cation of CK1 as a potential threonine 18 kinase
therefore opens up a new avenue of exploration to analyse the
physiological modi¢cation of this important regulatory site.
While murine p53 is also a substrate for CK1 in the absence
of serine 15 phosphorylation in vitro (at residues 4, 6 and 9
[23]), loss of the equivalent residues in human p53 does not
a¡ect the ability of CK1 to phosphorylate the protein (Fig.
1B). However, serine 20 (and possibly serine 37) may act as
phosphate acceptor in the human protein in vitro. Compar-
ison of the sequences of the ¢rst 42 amino acids of the murine
and human proteins (Fig. 4) reveals di¡erences which could
account for these observations. For example, proline residues
at positions 4 and 8 in the human protein may alter the
secondary structure such that the kinase does not e⁄ciently
interact with p53. Similarly, a glutamic acid residue at posi-
tion 17 (in both murine and human p53) may act as a recog-
nition determinant for phosphorylation of serine 20 (we do
not know whether serine 20 of murine p53 can also be phos-
phorylated by CK1). These di¡erences may re£ect genuine
variance in the way in which p53 proteins from di¡erent spe-
cies are regulated and add to a growing list of species-speci¢c
modi¢cations of p53 (discussed by Meek [3]). Alternatively,
when compared to the ability of CK1 to phosphorylate threo-
nine 18 in p53-15P, which is many orders of magnitude great-
er than unphosphorylated p53, the physiological relevance of
phosphorylation of these residues by CK1 may be question-
able. This is not to say that the residues themselves are not of
regulatory signi¢cance, only that the protein kinase(s) which
modify these sites in vivo may well be di¡erent from CK1. A
¢nal issue concerns the isoform(s) of CK1 which can modify
p53 in the cell. While previous data have indicated that the
delta and epsilon isoforms are preferentially active towards
murine p53 (at residues 4, 6 and 9 [24]), the use of a phos-
phorylated residue as a recognition determinant is not the
property of any speci¢c isoform(s) of CK1. It is therefore
possible that other CK1 isoforms may modify threonine 18
in vivo. Future studies should resolve these issues.
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